Takeda acquires investigational coeliac therapy
The Japanese pharma giant acquired the drug based on results from a phase IIa trial, in which the drug met its primary endpoint.
Read More
Tag: TAK-101
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
